What radiation field should be used for carcinoma of the vocal cord with subglottic extension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Radiation Field for Vocal Cord Carcinoma with Subglottic Extension

For vocal cord carcinoma with subglottic extension, the radiation field must encompass the entire larynx including the subglottic region, extending inferiorly to include prelaryngeal and pretracheal lymph nodes, with bilateral neck irradiation due to the higher risk of nodal involvement associated with subglottic disease.

Field Design and Technical Considerations

The presence of subglottic extension fundamentally changes your radiation planning from the simple 5×5 cm fields used for isolated T1 glottic lesions 1. This is a critical distinction that cannot be overlooked.

Primary Target Volume

  • Include the entire larynx from the hyoid bone superiorly to at least 2 cm below the inferior extent of disease
  • Extend inferiorly to cover the upper trachea and cricoid cartilage completely
  • The subglottic region requires particular attention to the prelaryngeal and pretracheal nodal basins, which are at higher risk with subglottic involvement 2

Nodal Coverage

Unlike pure T1-T2 glottic cancers where regional nodal involvement is unusual and single-modality treatment to the primary site is typically sufficient 3, subglottic extension mandates prophylactic nodal irradiation:

  • Bilateral neck treatment is required (levels II, III, IV, and VI)
  • The pretracheal (level VI) and paratracheal nodes are particularly important with subglottic disease 2
  • Prophylactic nodal RT should deliver approximately 50 Gy in 2 Gy fractions 4

Dose and Fractionation

For the primary tumor with subglottic extension:

  • Primary tumor dose: 66-70 Gy depending on tumor volume 4
  • Consider moderately accelerated fractionation (66-70 Gy in 33-35 fractions over 5.5-6 weeks) or hyperfractionation (80.5 Gy in 70 fractions of 1.15 Gy twice daily) for stage II disease 4
  • Standard fractionation remains acceptable but altered fractionation may improve local control 5

Critical Technical Points

Avoid the common pitfall of using small vocal cord-only fields when subglottic extension is present. While vocal cord-only RT (VC-RT) shows promise for pure glottic lesions with reduced tracheostomy rates 6, this approach is inappropriate for tumors with subglottic extension that require comprehensive laryngeal and nodal coverage.

Field Setup Requirements

  • Use parallel opposed lateral fields for the larynx and upper neck
  • Add an anterior lower neck field with midline block for level IV coverage
  • Ensure reproducible daily positioning with immobilization devices 1
  • Use contour-compensating devices (wedges) to optimize dose distribution 1

Treatment Planning Considerations

The subglottic extension classifies this as an unfavorable tumor requiring more aggressive treatment planning 3. This may represent a T2 or higher stage depending on the extent of involvement:

  • If vocal cord mobility is impaired, consider this deeply invasive disease
  • Concurrent chemoradiation may be indicated for unfavorable T2 lesions with significant subglottic extension 3
  • Primary surgery with adjuvant RT is an alternative for extensive subglottic involvement 4

Hypoxic Radiosensitizers

Consider adding hypoxic radiosensitizers, which have demonstrated improved locoregional control and disease-specific survival in randomized trials 4. This benefit applies regardless of fractionation regimen used.

Expected Outcomes and Toxicity

With appropriate field design including subglottic coverage:

  • Local control rates for primary subglottic carcinoma with RT alone: approximately 52-56% at 5 years 7
  • Ultimate local control with surgical salvage: 81% 7
  • Acute grade 3-4 mucositis occurs in approximately 40% with altered fractionation vs 25% with standard fractionation 4
  • Risk of tracheostomy for treatment-related edema exists, particularly with whole-larynx fields 6

The key is recognizing that subglottic extension removes this case from the favorable early glottic cancer category and requires comprehensive treatment planning with appropriate field coverage of at-risk nodal regions.

References

2
Research

Management of Subglottic Cancer.

Otolaryngologic clinics of North America, 2023

7
Research

Results of radiotherapy for primary subglottic squamous cell carcinoma.

International journal of radiation oncology, biology, physics, 2002

Related Questions

What are the risk factors for glottic laryngeal cancer in patients who do not smoke or drink alcohol?
Does the PET/CT scan show any evidence of throat (laryngeal or oropharyngeal) cancer?
In a 20‑week pregnant patient with a urinary tract infection likely pyelonephritis, should she be admitted for intravenous antibiotic therapy or managed with oral antibiotics?
Why am I experiencing fatigue after angioplasty while being treated for atrial fibrillation with metoprolol and amiodarone (QTc 450 ms)?
What is the most likely diagnosis in a 77‑year‑old male with a history of prostate disease, sleep disturbances, awaiting knee‑joint replacement, taking bromazepam (Lexaurin) and low‑dose lorazepam (Sanval) but no antihypertensive or cardiac medications, who presents with sudden onset vertigo, nausea/vomiting, a right‑ward fall, cervical spine tenderness, normal neurological examination, and stable vital signs?
For an adult patient without hyaluronic‑acid allergy, active skin infection, or recent facial laser treatment, which intradermal injection is more appropriate for improving pigmentation and reducing enlarged pores: Belotero Revive (hyaluronic‑acid filler) or Luhilo (dual‑weight hyaluronic acid with amino acids, peptides, niacinamide, and arbutin)?
For a patient with cold‑induced asthma who cannot tolerate albuterol (salbutamol) as a rescue medication, what is the best alternative therapy?
What are the imaging characteristics of a pretracheal lymph node on contrast-enhanced CT?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.